Ocumension Therapeutics Past Earnings Performance
Past criteria checks 0/6
Ocumension Therapeutics has been growing earnings at an average annual rate of 50.6%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 61.3% per year.
Key information
50.6%
Earnings growth rate
92.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 61.3% |
| Return on equity | -11.7% |
| Net Margin | -104.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results
Aug 15
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now
Jun 13Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable
Apr 29Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation
Mar 14Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates
Aug 29We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely
Jul 13Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?
Jun 02We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Jan 20We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Sep 27Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?
Jan 23
Revenue & Expenses Breakdown
How Ocumension Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 310 | -323 | 409 | 109 |
| 31 Mar 24 | 278 | -351 | 416 | 117 |
| 31 Dec 23 | 246 | -380 | 423 | 124 |
| 30 Sep 23 | 227 | -399 | 429 | 141 |
| 30 Jun 23 | 208 | -418 | 435 | 159 |
| 31 Mar 23 | 184 | -411 | 405 | 172 |
| 31 Dec 22 | 159 | -403 | 374 | 184 |
| 30 Sep 22 | 124 | -393 | 340 | 180 |
| 30 Jun 22 | 90 | -383 | 305 | 175 |
| 31 Mar 22 | 73 | -322 | 279 | 172 |
| 31 Dec 21 | 56 | -260 | 254 | 169 |
| 30 Sep 21 | 44 | -426 | 237 | 194 |
| 30 Jun 21 | 32 | -593 | 220 | 220 |
| 31 Mar 21 | 23 | -1,429 | 252 | 200 |
| 31 Dec 20 | 13 | -2,265 | 284 | 180 |
| 30 Sep 20 | 8 | -2,540 | 242 | 150 |
| 30 Jun 20 | 2 | -2,816 | 200 | 121 |
| 31 Mar 20 | 1 | -2,064 | 130 | 110 |
| 31 Dec 19 | 0 | -1,312 | 60 | 99 |
Quality Earnings: 1477 is currently unprofitable.
Growing Profit Margin: 1477 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1477 is unprofitable, but has reduced losses over the past 5 years at a rate of 50.6% per year.
Accelerating Growth: Unable to compare 1477's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1477 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.9%).
Return on Equity
High ROE: 1477 has a negative Return on Equity (-11.66%), as it is currently unprofitable.